CD163 and breast carcinoma: The number of CD68+ TAMs was higher in HER2+ breast cancer in comparison to HER2- breast cancer cases (p < 0.001), whereas the CD163+ TAM count was not significantly associated with HER2 status (p = 0.132) (Table 1).